60
Participants
Start Date
July 18, 2023
Primary Completion Date
October 1, 2027
Study Completion Date
October 1, 2027
Osimertinib
Osimertinib will be administered as 80 mg oral tablet once daily (from Day 2) until progression of disease or until a study intervention discontinuation criterion is met.
Amivantamab
Amivantamab will be administered as an IV infusion at 1050 mg (\< 80 kg body weight) or 1400mg (≥ 80 kg body weight) (in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1 to 2) and then every 2 weeks in subsequent cycles) until progression of disease or until a study intervention discontinuation criterion is met. The first cycle dose is spilt over 2 days- 350 mg on day 1 and 700 mg \[body weight \< 80 kg\] or 1050 mg \[body weight ≥ 80 kg\] on day 2.
Research Site, Taipei
Research Site, Taichung
Research Site, Yunlin
Research Site, Seoul
Research Site, Taipei
Research Site, Bangkok
Research Site, Bangkok
Research Site, Bangkok
Research Site, George Town
Research Site, Anyang-si
Research Site, Kota Bharu
Research Site, Kuantan
Research Site, Taichung
Research Site, Daegu
Research Site, Busan
Research Site, Chiang Mai
Research Site, Kuala Lumpur
Research Site, Kuala Lumpur
Research Site, Tainan City
Research Site, Kaohsiung City
Research Site, Songkhla
Research Site, Kuching
Research Site, Hong Kong
Research Site, Singapore
Research Site, Singapore
Research Site, Hong Kong
Research Site, Hong Kong
Research Site, Shatin
Research Site, Seoul
Lead Sponsor
Collaborators (1)
Parexel
INDUSTRY
AstraZeneca
INDUSTRY